Papilloma Viral Infection Clinical Trial
Official title:
Study of the Impact of a School Program Combining - Promotion of HPV Vaccination and HPV Vaccine Offer in Middle School - on Adherence to HPV Vaccination in Middle School Students
Cervical cancer (CCU) is the fourth most common cancer in women worldwide. In Reunion island, CCU is the third leading cause of cancer in women (standardized incidence rate on the world population (TIS) in 2013 of 10.3 / 100,000) and is the eighth deadliest cancer with a rate standardized mortality of 4.8 / 100,000, almost three times higher than in mainland France where it was 1.7 / 100,000 in 2018. CCU results from infection with the human papillomavirus (HPV), which is the most common sexually transmitted viral infection. CCU prevention is mainly based on cervical smear screening and anti HPV vaccination (VHPV) which has demonstrated its effectiveness on the prevalence of HPV carriage, but also on incidence of condyloma or intermediate grade dysplasia. Since HPV is mainly transmitted sexually, it is important to vaccinate before the start of sex. In Reunion island, the HPV vaccination coverage rate is the lowest in France, estimated by Public Health France at 8.1% among girls aged 16 years in 2018, while the already low national average was established 23.7%. Thus, in view of the epidemiological situation in Reunion island (high incidence and mortality for the CCU, very low VHPV coverage rate), we thought it would be interesting to study the impact of a health promotion program sex and prevention of sexually transmitted infections (STIs) including papillomavirus-related pathologies, with a program to promote HPV vaccination among young students in middle school.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03584308 -
Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal
|
Phase 2 | |
| Completed |
NCT05078554 -
HPV and Male Homosexuality in General Practice?
|
||
| Not yet recruiting |
NCT06416150 -
Reducing Urban Cervical Cancer Disparities
|
N/A | |
| Completed |
NCT02114385 -
A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)
|
Phase 3 | |
| Recruiting |
NCT05916911 -
Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)
|
Phase 4 | |
| Completed |
NCT01030562 -
Immunogenicity of Off-Schedule Dosing of HPV Vaccine
|